Article
A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
Antiviral research - 1 Oct 2017
Mathur Poonam, Comstock Emily, McSweegan Edward, Mercer Natalia, Kumar Nongthombam Suraj, Kottilil Shyamasundaran
Abstract excerpt
The past five years have seen a revolution in the treatment of chronic hepatitis C, as short duration oral regimens of direct-acting antiviral drugs (DAAs), with nearly 100% cure rates for all genotypes, have replaced longer courses of ribavirin and injected interferon. Although initially very expensive, these DAAs are now becoming available in generic equivalents in countries with large numbers of chronically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.